811812-57-4

Basic information

• Product Name: Pyridine, 2-(4-piperidinylMethyl)-
• Synonyms: Pyridine, 2-(4-piperidinylMethyl)-
• CAS NO: 811812-57-4
• Molecular Formula: C₁₁H₁₆N₂
• Molecular Weight: 176.25814
• Mol File: 811812-57-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 288.9±20.0 °C(Predicted)
• Appearance: /
• Density: 1.012±0.06 g/cm3(Predicted)
• PKA: 10.46±0.10(Predicted)
• CAS DataBase Reference: Pyridine, 2-(4-piperidinylMethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-(4-piperidinylMethyl)-(811812-57-4)
• EPA Substance Registry System: Pyridine, 2-(4-piperidinylMethyl)-(811812-57-4)

Safety Data

• Hazardous Substances Data: 811812-57-4(Hazardous Substances Data)

Upstream product

• 333986-08-6 tert-butyl 4-((pyridin-2-yl)methyl)piperidine-1-carboxylate 
• 109-04-6 2-bromo-pyridine 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.